148 related articles for article (PubMed ID: 27126186)
1. Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation.
An C; Zhang J; Chu H; Gu C; Xiao F; Zhu F; Lu R; Shi H; Zhang H; Yi X
Pathol Oncol Res; 2016 Oct; 22(4):763-8. PubMed ID: 27126186
[TBL] [Abstract][Full Text] [Related]
2. Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial.
Jiang T; Wang P; Zhang J; Zhao Y; Zhou J; Fan Y; Shu Y; Liu X; Zhang H; He J; Gao G; Mu X; Bao Z; Xu Y; Guo R; Wang H; Deng L; Ma N; Zhang Y; Feng H; Yao S; Wu J; Chen L; Zhou C; Ren S
Signal Transduct Target Ther; 2021 Oct; 6(1):355. PubMed ID: 34650034
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of gefitinib (Iressa(®)) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer.
Han JY; Lee SH; Lee GK; Yun T; Lee YJ; Hwang KH; Kim JY; Kim HT
Cancer Chemother Pharmacol; 2015 Mar; 75(3):475-83. PubMed ID: 25552401
[TBL] [Abstract][Full Text] [Related]
4. Gefitinib vs Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Variant Lung Cancer-Long-Term Results of a Randomized Clinical Trial.
Noronha V; Patil V; Menon N; Shah M; Chougule A; Peelay Z; Prabhash K
JAMA Oncol; 2024 Jun; 10(6):824-826. PubMed ID: 38662354
[TBL] [Abstract][Full Text] [Related]
5. Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer.
Traynor AM; Schiller JH; Stabile LP; Kolesar JM; Eickhoff JC; Dacic S; Hoang T; Dubey S; Marcotte SM; Siegfried JM
Lung Cancer; 2009 Apr; 64(1):51-9. PubMed ID: 18701186
[TBL] [Abstract][Full Text] [Related]
6. Effect of AGEs-RAGE system on the efficacy of PD-1 inhibitors in the treatment of driver-gene mutation negative advanced non-squamous non-small cell lung cancer.
Li X; Wang G; Sun X; Feng Y; Wang L; Sun G; Qiao H
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):155-160. PubMed ID: 38279452
[TBL] [Abstract][Full Text] [Related]
7. Clinical analysis of anlotinib as first-line treatment for elderly patients with advanced lung adenocarcinoma without driver gene mutations.
Zhu J; Xie Q; Zhong A; Le Y
Anticancer Drugs; 2022 Jan; 33(1):e584-e589. PubMed ID: 34387607
[TBL] [Abstract][Full Text] [Related]
8. Gefitinib-induced Myositis: A Novel Case Report.
Sakamoto T; Saito Y; Takekuma Y; Kikuchi E; Sugawara M
Yakugaku Zasshi; 2023; 143(7):617-620. PubMed ID: 37394456
[TBL] [Abstract][Full Text] [Related]
9. The Impact of Baseline Vitamin D Level in Patients Receiving Gefitinib-Directed Therapy for EGFR-Mutant Non-Small-Cell Lung Cancer.
Noronha V; Kolkur M; ArunKumar R; Adak S; Patil V; Menon N; Shah M; Prabhash K
Clin Med Insights Oncol; 2024; 18():11795549241254460. PubMed ID: 38827521
[TBL] [Abstract][Full Text] [Related]
10. Exploration of efficacy of different therapy regimens for advanced NSCLC patients with KRAS mutation in the first-line treatment.
Wang K; Xu M; Wang Y; Xu C; Hao Y; Song Z
Clin Transl Oncol; 2024 Apr; ():. PubMed ID: 38625494
[TBL] [Abstract][Full Text] [Related]
11. Almonertinib plus chemotherapy
Fang X; Xiang Y; Lu K
Front Oncol; 2023; 13():1248690. PubMed ID: 37752994
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Sintilimab Combined with Pemetrexed and Platinum Chemotherapy in Non-Small Cell Lung Cancer Patients.
Nio X; Fengo J; Yao J
Altern Ther Health Med; 2024 Jun; ():. PubMed ID: 38870510
[TBL] [Abstract][Full Text] [Related]
13. Survival outcomes of alternate dosing schedule of pemetrexed as maintenance therapy in NSCLC: Single institution experience.
Faber MG; Wang C; Kommi Reddy S; Meagher A; Early A; Chen H; Dy GK
Lung Cancer; 2022 Mar; 165():49-53. PubMed ID: 35085984
[TBL] [Abstract][Full Text] [Related]
14. Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases.
He Y; Sun W; Wang Y; Ren S; Li X; Li J; Rivard CJ; Zhou C; Hirsch FR
Onco Targets Ther; 2016; 9():2409-14. PubMed ID: 27143936
[TBL] [Abstract][Full Text] [Related]
15. Feasibility study of first-line chemotherapy using Pemetrexed and Bevacizumab for advanced or recurrent nonsquamous non-small cell lung cancer in elderly patients: TORG1015.
Kozuki T; Nogami N; Kitajima H; Iwasawa S; Sakaida E; Takiguchi Y; Ikeda S; Yoshida M; Kato T; Miyamoto S; Sakamaki K; Shinkai T; Watanabe K
BMC Cancer; 2016 May; 16():306. PubMed ID: 27177035
[TBL] [Abstract][Full Text] [Related]
16. Safety of gefitinib in non-small cell lung cancer treatment.
Hsiue EH; Lee JH; Lin CC; Yang JC
Expert Opin Drug Saf; 2016 Jul; 15(7):993-1000. PubMed ID: 27212579
[TBL] [Abstract][Full Text] [Related]
17. Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other Platinum-Based Doublet Regimens in Elderly East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Lu S; Cheng Y; Zhou CC; Wang J; Chih-Hsin Yang J; Zhang PH; Zhang XQ; Wang X; Orlando M; Wu YL
Clin Lung Cancer; 2016 Sep; 17(5):e103-e112. PubMed ID: 27236385
[TBL] [Abstract][Full Text] [Related]
18. Treatment of EGFR-Mutant Lung Cancers After Progression in Patients Receiving First-Line EGFR Tyrosine Kinase Inhibitors : A Review.
Piotrowska Z; Sequist LV
JAMA Oncol; 2016 Jul; 2(7):948-54. PubMed ID: 27196961
[TBL] [Abstract][Full Text] [Related]
19. Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy.
Verdaguer H; Tabernero J; Macarulla T
Ther Adv Med Oncol; 2016 May; 8(3):230-42. PubMed ID: 27239240
[TBL] [Abstract][Full Text] [Related]
20. Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer.
Lilenbaum RA; Horn LA
J Natl Compr Canc Netw; 2016 May; 14(5 Suppl):672-4. PubMed ID: 27226511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
